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ABSTRACT 
Background: Preclinical and epidemiological evidence suggests a role for statins in the treatment of breast 
cancer. However, uncertainties over the benefit of initiating statin use in the adjuvant treatment setting 
remain. This study investigates associations between statin-use initiated after a breast cancer diagnosis, and 
breast cancer-specific mortality. Methods: Women, with stage I-III breast cancer, aged 50-80, and not 
prescribed a statin prior to diagnosis were identified from the National Cancer Registry of Ireland (N=4,243). 
Women initiating post-diagnostic statin use were identified from linked national prescription refill data 
(N=837). Multivariable Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% 
confidence intervals (CIs) for associations between de-novo post-diagnosis statin use and mortality. Results: 
The median duration of post-diagnostic statin use was 6.7 years and the mean on-treatment exposure 
intensity was 86.3%. In multivariable analyses no association was found between post-diagnostic statin 
initiation and breast cancer-specific mortality (HR 0.88, CI 0.66, 1.17). There was no effect modification by 
statin type (hydrophilic/lipophilic), or ER status. Similarly, in analyses of high-intensity use (≥80% for longer 
than 12 consecutive months) we found no association with breast cancer-specific mortality for all statins 
combined (HR 1.03, 95%CI 0.71, 1.50), and separately for hydrophilic/lipophilic statins. Conclusion: The results 
from our study suggest that initiating statin use after a diagnosis of stage I-III breast cancer is not associated 
with a reduction in breast cancer-specific mortality. Future studies should assess whether there are molecular 
subgroups of patients for whom statin use may be beneficial. 
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INTRODUCTION 
Randomized trials have demonstrated that statins, or 3-hydroxy-3-methylglutaryl coenzyme-A reductase 
(HMGCR) inhibitors, are effective for the reduction of cholesterol and prevention of cardiovascular disease1. 
Statins inhibit the rate-limiting step of the cholesterol biosynthesis pathway, leading to reduced levels of 
mevalonate and its downstream products2. Many of these downstream products play important roles in 
cellular processes such as membrane integrity, protein synthesis, and cell signalling, and their inhibition by 
statins may have anticancer effects3,4. There is also some epidemiological evidence to suggest that statins 
could have a role in the management of breast cancer5–12, with one study reporting a statistically significant 
reduction in recurrence for users of simvastatin, a lipophilic statin7. However, uncertainties over the benefit of 
statins in the adjuvant breast cancer setting remain, as any possible effect may be limited to reductions in 
locoregional recurrence7 and to date no studies of statin use have reported a reduction in breast cancer-
specific mortality8,11,12. Additionally, most studies have included women who initiated statin use prior to their 
breast cancer diagnosis, and it is unclear from their results what benefit may be attributable to the post-
diagnostic initiation of statin treatment6–12. A clearer understanding of the effect of post-diagnostic statin 
initiation on breast cancer-specific mortality is necessary to inform the undertaking of clinical studies of statins 
for the adjuvant treatment of breast cancer13. 
In a large cancer registry-based cohort of women with incident breast cancer, this study aimed to 
measure associations between statin use initiated after a breast cancer diagnosis (de-novo), and breast 
cancer-specific and all-cause mortality, and to investigate whether associations between statin use and 
mortality are modified by the solubility characteristics of statins or breast tumour characteristics 
METHODS 
SETTING & DATA SOURCES 
This study was carried out using patient records from the National Cancer Registry Ireland (NCRI), which have 
been linked to individual-level prescription dispensing data from Ireland’s Primary Care Reimbursement 
Services (PCRS) pharmacy claims database. These data have been described previously14. Briefly, the NCRI 
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records details about all cancers diagnosed in the population normally resident in Ireland. For each tumour 
diagnosis, hospital-based tumour registration officers (TRO) collect information on patient characteristics, 
tumour characteristics and treatment received. Information on date and cause of death are obtained from 
linkage to death certificates. The completeness of cancer registration is estimated to be at least 97% overall 
and higher for breast cancer15. The use for research of anonymised data held by the NCRI is covered by the 
Health (Provision of Information) Act 1997. 
The PCRS is responsible for financial reimbursement of dispensed medication claims made under the 
General Medical Services (GMS) community drug scheme. The GMS scheme provides subsidized healthcare, 
including prescription medications at no or minimal cost, to approximately one third of the Irish population. 
Eligibility for the scheme is assessed by a combination of age and means test. The PCRS pharmacy claims 
database records details, including quantity and dose, of all prescription drugs dispensed to patients with 
eligibility for the scheme. Drugs are coded according to WHO–ATC classifications16.  
COHORT & EXPOSURE DEFINITIONS 
The study population comprised of women with a diagnosis of stage I-III breast cancer (ICD-10 C50) between 
1st January 2001 and 31st December 2011. Women were included in the study population if they were aged 
between 50-80 years at diagnosis; had GMS eligibility from at least 1 year prior to diagnosis; and no history of 
invasive cancer, other than non-melanoma skin cancer. The study population was restricted by age because 
younger women are less likely to be prescribed statins and older women are less likely to receive definitive 
cancer staging or treatment17. Prescriptions for statins dispensed in the year prior to breast cancer diagnosis 
were identified from the PCRS database, and women receiving statin therapy during this time were excluded 
from the study population.  
Within the remaining cohort of women we identified de-novo post-diagnostic statin exposure from 
prescriptions dispensed between breast cancer diagnosis and the end of follow up (death or 31st December 
2012, whichever occurred first). For each day of follow-up, we calculated statin dosing intensity based on the 
number of days’ supply of statin received in the prior year. These statin exposure histories were used to define 
the following time varying exposure categories: i) women were identified as exposed (yes/no) from the date 
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they received their first statin prescription following diagnosis; ii) women were identified as having high-
intensity exposure from the first date they had taken a statin at an intensity of ≥80%, for longer than 1 year. 
Once allocated to an exposure category, women remained in this category to the end of follow-up. 
COVARIATES & OUTCOMES 
The following patient, tumour and treatment characteristics were obtained from the NCRI database: age 
(years) at diagnosis, smoking status at diagnosis (never, past, current, unspecified), tumour stage (I, IIa, IIb, IIIa, 
IIIb-c), histologic tumour grade (low, intermediate, high, unspecified), oestrogen (ER), progesterone (PR) and 
human epidermal growth factor-2 (HER-2) receptor status (positive, negative, unspecified) and receipt of 
chemotherapy (yes, no) or radiotherapy (yes, no) in the year after diagnosis. Anti-oestrogen therapy started in 
the year after breast cancer diagnosis (yes, no) was identified using the PCRS database. The PCRS database was 
also used to identify other prescribed, and potentially confounding medication use in the year prior to 
diagnosis (exposed, unexposed); aspirin18, anti-diabetics,18 non-steroidal anti-inflammatory drugs19 and 
bisphosphonates20. The number of drug classes (4th level WHO-ATC classification) dispensed in the year before 
diagnosis was used as a proxy measure of co-morbidity 21.  Death certificates were used to determine the date 
and cause of death (all-cause or breast cancer-specific). Breast cancer-specific deaths were identified using 
SEER definitions for cancer-specific mortality (Table S1)22. 
STATISTICAL ANALYSIS 
All analyses were performed using SAS® v9.3 (SAS® Institute Inc, Cary, NC). The proportion of de-novo post-
diagnostic statin users was tabulated for each covariate and differences in the rates of post-diagnostic statin 
initiation across covariates were compared using univariate Poisson regression. Results were regarded as 
significant at a two-sided α-level of 0.05. The length of time from diagnosis to statin initiation was calculated 
and Kaplan Meier analysis was used to estimate the median duration of statin use from initiation to last 
exposure (censored at death or end of follow-up). The overall intensity of statin exposure while on treatment 
was calculated by expressing the number of days’ supply received as a proportion of the number of days from 
initiation to last exposure. 
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For survival analyses, person time was calculated from the date of breast cancer diagnosis to the end 
of follow-up. Multivariate Cox regression models were used to estimate adjusted hazard ratios (HR) and 95% 
confidence intervals (CI) for associations between post-diagnosis de-novo statin use and breast cancer-specific 
and all-cause mortality. Patients were categorised as statin exposed (yes/no) from the time they received their 
first statin prescription. These exposures were lagged in analyses to reduce the possibility that changes in 
breast cancer prognosis or treatment, for example a breast cancer recurrence or approaching death, 
influenced a patient’s or prescriber’s decision to initiate or continue statin therapy23. The exposure lag time 
was set at 2 years, the median survival time after a breast cancer recurrence24, and varied in sensitivity 
analyses (0, 1, 3, 4 years). The previously described covariates were selected for inclusion in multivariable 
survival analyses, based on prior knowledge of patient and clinical characteristics associated with breast 
cancer-specific mortality. 
We conducted the following subgroup analyses. Firstly, we stratified analyses by high/low exposure 
intensity, as described above (time varying, lagged by 2 years). Secondly, analyses were stratified by statin 
solubility: lipophilic (atorvastatin, fluvastatin, simvastatin), hydrophilic (pravastatin, rosuvastatin), both25. Prior 
studies have suggested that only lipophilic statin use is associated with improved breast cancer outcomes7. 
Thirdly, analyses were stratified by ER status (positive, negative, unspecified) as preclinical studies have 
reported differential effects of statins on ER positive and negative breast cancer cell lines26,27. The presence of 
effect modification was assessed with the inclusion of an interaction term in the multivariable model. 
We conducted sensitivity analyses in which the high intensity statin exposure was defined as ≥80% 
intensity for longer than two consecutive years; and the time without pre-diagnostic statin exposure was 
extended from 1 to 3 years. To explore our results in further detail we conducted a post-hoc analysis of 
lipophilic/hydrophilic statin use stratified by high/low exposure intensity.  
RESULTS 
COHORT & EXPOSURE CHARACTERISTICS 
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We identified 4,243 women from the linked PCRS-NCRI database with stage I-III breast cancer, aged between 
50 and 80, and not receiving a statin prescription prior to their diagnosis (Figure 1). The median post-
diagnostic follow-up for these patients was 4.9 years and their characteristics are described in Table 1. Within 
this cohort, we identified 837 (19.7%) women who initiated statin use after their breast cancer diagnosis. The 
overall rate of de-novo statin initiation was 42.8 new users per thousand patient years. Rates of statin 
initiation were significantly higher in women with a history of diabetes, lower tumour stage at diagnosis and 
positive oestrogen receptor status. The median length of time from diagnosis to statin initiation was 2.1 years, 
the median duration of statin use was 6.7 years and the mean on-treatment exposure intensity was 86.3% 
(Table 2). Person time attributed to de-novo statin users and non-users was 2,426 and 12,369 years 
respectively. 
DE-NOVO STATIN USE AND MORTALITY 
The results from univariate and multivariate analyses of statin-use on breast cancer-specific and all-cause 
mortality, adjusting for patient and tumour characteristics, co-prescribed medications, and comorbidities, are 
shown in Table 2. In these we found no association between de-novo statin initiation and breast cancer-
specific mortality (HR 0.88, 95%CI 0.66, 1.17). Subgroup analyses in women taking statin at an intensity of 
≥80% for longer than 12 consecutive months also yielded null associations with breast cancer-specific 
mortality (HR 1.04, 95%CI 0.71, 1.51). The median length of time to statin initiation in this high intensity 
exposure group was 2.0 years, the median duration of statin use was 8.5 years and the mean on-treatment 
exposure intensity was 89.2%. Our results were unchanged in sensitivity analyses i) varying the exposure lag 
time from 0 to 4 years; ii) modifying the definition of high intensity exposure to ≥80% for longer than two 
consecutive years; and iii) increasing the pre-diagnostic period without statin exposure from one to three years 
(Table 3). 
The results from subgroup analyses stratified by statin solubility characteristics (hydrophilic, lipophilic, 
or both) are presented in Table 2. We found no statistically significant associations between hydrophilic or 
lipophilic statin use and breast cancer-specific mortality. There appeared to be a nominal reduction in breast 
cancer-specific mortality for patients using lipophilic statins and we explored this further in a post-hoc analysis 
of lipophilic/hydrophilic statin use stratified by high/low exposure intensity. In this analysis, high intensity 
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lipophilic statin use (median duration of use 5.8 years; mean on-treatment exposure intensity was 88.2%) was 
not associated with a reduction in breast cancer-specific mortality (HR 1.05, 95%CI 0.67, 1.63; Table 2). There 
was no evidence of effect modification by ER status (Pinteraction=0.69). 
DISCUSSION 
In this cancer registry-based cohort of newly diagnosed breast cancer patients with stage I-III disease, we did 
not observe an association between de-novo post-diagnostic statin use and a reduction in breast cancer-
specific mortality. Our study population consisted of 4,243 women not taking a statin prior to their breast 
cancer diagnosis, of whom 837 initiated de-novo statin use. Within statin initiators we observed long durations 
of treatment, and high levels of use while on treatment, which suggests that our results are unlikely to be due 
to inadequate statin exposure. Additionally, in stratified analyses of high-intensity statin use (median duration 
>8yrs, mean treatment intensity >89%) we found consistent null or close to null estimates for all statins 
combined, and separately for hydrophilic or lipophilic statins. A statistically significant association with 
reduced breast cancer-specific mortality was observed in the low-intensity lipophilic statin subgroup. However 
this finding is very unlikely to be causal as the median duration of exposure in this subgroup was only six 
months and, as noted above, high-intensity lipophilic statin use was not associated with a reduction in breast 
cancer-specific mortality.  
Overall, our results are consistent with those from the small number of prior studies that have 
specifically examined de-novo post-diagnostic statin use and breast cancer-specific mortality5,11. In these 
studies, statin use initiated after diagnosis was not associated with a statistically significant improvement in 
breast cancer outcomes. Studies of de-novo statin use address the clinically relevant question of whether 
there is a benefit associated with initiating statin treatment after a breast cancer diagnosis, and their results 
may inform the design and conduct of clinical studies in the adjuvant setting. Several studies have also 
examined post-diagnostic statin use in women who initiated statin treatment prior to their breast cancer 
diagnosis,6–12 with some reporting large statistically significant reductions in breast cancer recurrence and 
mortality7,9, in particular for users of lipophilic statins7. However, it is unclear from their results what benefit 
may be attributable to the post-diagnostic initiation of statin treatment. 
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The results from observational studies of statin use and breast cancer outcomes must be interpreted 
with care as there is evidence that statins are preferentially prescribed for, and taken by, patients who make 
better healthcare choices, engage in healthier behaviours and have superior health outcomes28–31. This has 
been shown to cause appreciable residual confounding if unaccounted for in analyses, and a tendency to 
overestimate any beneficial effect of statins32,33. Observational studies have frequently attributed a variety of 
non-cardiovascular health benefits to statin use30,34,35 including protection from cancer incidence and 
mortality36,37. However, secondary analyses of randomized trial data have not confirmed these 
associations35,38, and many of the findings from observational studies have subsequently been attributed to 
the preferential prescribing of statins to healthier patients28,35. There is some evidence to indicate that statins 
are also selectively prescribed for women with better prognosis breast cancer. In studies by Snyder et al, 
women with later stage breast cancer were considerably less likely to be screened for hypercholesterolemia 
after their diagnosis39,40, and in our study women with later stage disease had a significantly lower rate of post-
diagnostic statin initiation (Table 1). Patients with poor prognosis cancer are also more likely to discontinue 
statin use after their diagnosis41. Fully accounting for the selective prescribing of statins in analyses of breast 
cancer outcomes is challenging. For example, in the only study reporting a significant association between 
statin use and breast cancer recurrence7, the observed benefit was solely attributable to reductions in 
locoregional (ipsilateral, lymph node) and contralateral recurrences, with no reduction in distant recurrence. 
While standard baseline prognostic information (e.g. stage, grade, receptor status) was adjusted for, there are 
additional strong clinical predictors of locoregional recurrence (such as the presence of residual disease after 
neo-adjuvant therapy, sub-optimal lymph node evaluation at surgery, and the presence of positive tumour 
margins after surgery42–45), which may influence the prescribing and use of statins. Additionally, locoregional 
recurrences are strongly influenced by patients’ healthcare choices, in particular decisions to forego additional 
surgery to re-excise positive tumour margins45 and non-compliance with adjuvant radiation46,47, chemotherapy 
or hormonal therapy48. The presence of residual confounding must therefore be carefully considered in studies 
reporting beneficial effects of statins on breast cancer outcomes. Finally it should also be borne in mind that 
locoregional and contralateral recurrences are associated with considerably lower mortality than distant 
metastatic recurrences46,49,50. Therefore, the reductions in locoregional and contralateral recurrence observed 
in some studies of statins may not translate in to similar reductions in breast cancer-specific mortality. This 
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may also explain differences between the mortality results we report here and those from previous studies 
examining breast cancer recurrence7. 
While we observed no overall association between de-novo statin use and breast cancer-specific 
mortality in an unselected population, there may be specific molecular subgroups of patients for whom statin 
treatment could be beneficial. In a window-of-opportunity trial by Bjarnadottir et al., in which women were 
given high dose atorvastatin (80mg/day) for two weeks between diagnosis and surgical resection of their 
breast tumour, statin treatment was associated with a statistically significant reduction in Ki67 proliferation 
index among the subgroup of women with tumours expressing HMGCR.51 However, while the mean absolute 
reduction in Ki67 observed in this subgroup (4.6%) was statistically significant, it is less than that obtained with 
established adjuvant treatments for breast cancer, such as hormonal therapy (63.9%), and the clinical 
relevance of this observation is unclear52. Nevertheless, it would be worthwhile to evaluate tumour expression 
of HMGCR as a predictor of response to statin treatment in future observational studies.  
Some,7,12 but not all,9,10 studies have suggested that associations between statin use and breast 
cancer outcomes may also be modified by the solubility characteristics of individual statins. However, in our 
analyses we did not observe a difference in effect between hydrophilic and lipophilic statins, overall or with 
high intensity use. The reasons for this between-study heterogeneity are unclear, although differences in the 
timing of cohort enrolment should be considered. The availability and indications for use of hydrophilic and 
lipophilic statins have varied considerably over time and this may result in differences between cohorts in the 
prescribing patterns of hydrophilic versus lipophilic statins53,54. 
Our study has a number of strengths, including the use of prospectively collected breast cancer 
outcome and prescription refill exposure data. However, there are also some potential limitations. We could 
not verify whether women took the medication they received and non-compliance may have resulted in 
misclassification of exposure. However, we expect that women are unlikely to continue filling prescriptions for 
a medication they are no longer taking. We did not have information on lifestyle factors that may influence 
disease progression, such as obesity, and the potential for residual confounding in our analyses should be 
considered. Finally, when generalising our results, it must be remembered that our study population was a 
subset of breast cancer cases defined by age and socioeconomic eligibility for the GMS scheme.  
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In conclusion, the results from our study suggest that initiating statin use after a diagnosis of stage I-III 
breast cancer is not associated with a reduction in breast cancer-specific mortality. We also observed no 
evidence of effect modification by statin solubility or hormone receptor characteristics. 
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TABLE S1: STUDY COVARIATE / OUTCOME DEFINITIONS 
 
 
Study Covariate / Outcome Definition 
  
Drug Exposures WHO ATC Drug Codes 
Aspirin B01AC06, M01BA03, N02BA01, N02BA51, N02BA71 
Anti-diabetic A10 
Bisphosphonate M05BA, M05BB 
Hydrophilic Statin C10AA03, C10AA07, C10BX02,  
Lipophilic Statin C10AA01, C10AA02, C10AA04, C10AA06, C10BA, C10BX01,  C10AA05,  C10BX03 
Other NSAID M01A 
Hormonal Therapy L02BA01, L02BA02, L02BA03, L02BG03, L02BG04, L02BG06 
  
Tumor Receptor Status NCRI Coding Definition 
ER, PR  Estrogen and progesterone receptor activity was defined as positive if recorded by the NCRI 
database as unclear/possibly, some receptor activity or positive/strong.  
  
HER2 HER2 receptor activity was defined as positive by immunohistochemistry if recorded by the 
NCRI database as score 2+, weak/strong positive or weak/strong complete membrane 
staining in >10% of tumor cells. HER2 receptor activity was defined as positive by 
fluorescence in-situ hybridization if recorded by the NCRI database as weak/strong positive 
or some/strong amplification. Where IHC & FISH results were recorded, FISH results were 
used. 
  
Breast Cancer-Specific Mortality ICD10 Codes 
From Howlader et al. 55 B201-B219;  
 C50, D05, D24, D486 
 C445, D225, D485 
 C000–C444, C446–C499, C510–D049, D060–D224, D226–D239, D250–D484, D487–D489 
 N610–N649 
14 
 
 
 
Age ≤ 80 years 
N = 7,228 
Women of any age with National Cancer Registry Ireland database 
record of invasive breast cancer, diagnosed January 1
st
 2001 - December 
31
st
 2011, and General Medical Services eligibility starting at least 1 year 
prior to diagnosis. Excluding women with prior invasive cancer
A
, or 
breast cancer identified at death. 
N = 10,319 
Age ≥ 50 years 
N = 9,151 
Stage I-III breast cancer at diagnosis 
N = 6,314 
No statin use in the year prior to diagnosis 
N = 4,243
B
 
 
Figure 1. Study inclusion/exclusion criteria. 
A) With the exception of non-melanoma skin cancer.  
B) Patients with an event prior to the completion of a 2 year exposure lag were excluded from the main analyses. 
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TABLE 1: CHARACTERISTICS OF WOMEN INCLUDED IN THE STUDY COHORT, BY POST-DIAGNOSIS STATIN EXPSOURE, WITH 
STATIN INITIATION RATE 
  De-novo statin use post breast cancer diagnosis A, B 
Characteristic  
Non-user 
N = 2,759 
User 
N = 837 
Initiation rate 
(per 1000 person years) 
        
Age in years  Median (IQR) 66  (58, 73) 65 (58,  72)  - 
Comorbidity score C  Median (IQR) 6 (3, 11) 7 (3, 11)  - 
        
Smoking – (%)  Current 583 (21.1) 171 (20.4)  41.3 
 Past 306 (11.1) 106 (12.7)  47.5 
 Never 1,324 (48.0) 422 (50.4)  43.8 
 Unspecified 546 (19.8) 138 (16.5)  38.8 
        
Aspirin – (%) C Yes 432 (15.7) 153 (18.3)  49.2 
 No 2327 (84.3) 684 (81.7)  41.6 
        
NSAID – (%) C  Yes 1,178 (42.7) 384 (45.9)   44.8 
 No 1581 (57.3) 453 (54.1)  41.2 
        
Anti-diabetic – (%) C * Yes 60 (2.2) 38 (4.5)  74.7 
 No 2699 (97.8) 799 (95.5)  41.9 
        
Bisphosphonate – (%) C Yes 198 (7.2) 46 (5.5)  39.4 
 No 2561 (92.8) 791 (94.5)  43.0 
        
Tumour stage – (%) D * I 917 (33.2) 297 (35.5)  44.1 
 IIa 843 (30.6) 297 (35.5)  47.5 
 IIb 610 (22.1) 162 (19.4)  38.0 
 IIIa 166 (6.0) 40 (4.8)  39.6 
 IIIb-c 223 (8.1) 41 (4.9)  31.7 
        
Tumour grade – (%) Low 301 (10.9) 101 (12.1)  44.8 
 Intermediate 1,357 (49.2) 416 (49.7)  43.9 
 High 866 (31.4) 254 (30.4)  42.4 
 Unspecified 235 (8.5) 66 (7.9)  35.8 
        
ER – (%) * Negative  471 (17.1) 110 (13.1)  35.3 
 Positive 2,028 (73.5) 610 (72.9)  43.7 
 Unspecified 260 (9.4) 117 (14.0)  47.5 
        
PR – (%) Negative  717 (26.0) 179 (21.4)  39.2 
 Positive 1,393 (50.5) 415 (49.6)  44.7 
 Unspecified 649 (23.5) 243 (29.0)  42.7 
        
HER2 – (%)  Negative  1,679 (60.9) 419 (50.1)  40.8 
 Positive 339 (12.3) 99 (11.8)  44.7 
 Unspecified 741 (26.9) 319 (38.1)  45.1 
        
Chemotherapy – (%) E Yes 1,123 (40.7) 344 (41.1)  43.2 
 No 1636 (59.3) 493 (58.9)  42.5 
        
Anti-Oestrogen – (%) E Yes 2,065 (74.9) 642 (76.7)  43.8 
 No 694 (25.1) 195 (23.3)  39.9 
        
 
*Difference in statin initiation rate P<0.05 (Poisson regression) 
IQR: Inter-Quartile Range. ER: Oestrogen Receptor. PR: Progesterone Receptor. HER2: Human Epidermal Growth Factor Receptor 2. NSAID: Non-Steroidal Anti-
Inflammatory Drug. 
A) No statin use in the year prior to diagnosis and at least one statin prescription received between diagnosis and the end of follow-up, 31st December 2011. 
B) Patients identified as statin users / non-users after lagging exposure by 2 years. 
C) In the year prior to breast cancer diagnosis. 
D) AJCC Cancer Staging Manual 6th Edition. Springer, 2002. 
E) In the year post breast cancer diagnosis. 
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TABLE 2: UNIVARIATE AND MULTIVARIATE HAZARD RATIOS FOR ASSOCIATION BETWEEN DE-NOVO POST-DIAGNOSTIC STATIN USE AND MORTALITY 
De-novo post-diagnostic  
statin exposure definitions 
 All-cause mortality  Breast cancer-specific mortality 
N 
Years to  
treatment 
initiation 
(median) 
Years on 
treatment 
(median) 
On-treatment 
exposure 
intensity 
(mean %) 
Follow-up 
(person  
years) 
Deaths  
(rate) A 
Univariate HR  
(95%CI) 
Multivariate HR  
(95%CI) B 
 
Deaths  
(rate) A 
Univariate HR  
(95%CI) 
Multivariate HR  
(95%CI) B 
                    
 Statin exposure – yes/no C                   
 Non-user 2,759 - - - 12,369 692 (55.9) Ref - Ref -  398 (32.2) Ref - Ref - 
 Statin user 837 2.1 6.7 86.3 2,426 128 (52.8) 0.93 (0.77, 1.14) 1.00 (0.82, 1.21)  56 (23.1) 0.79 (0.59, 1.06) 0.88 (0.66, 1.17) 
                    
 Dosing intensity C                   
 Non-user 2,759 - - - 12,369 692 (55.9) Ref - Ref -  398 (32.2) Ref - Ref - 
 Statin user - low intensity 346 2.4 0.7 82.1 1,165 54 (46.4) 0.82 (0.62, 1.08) 0.88 (0.67, 1.17)  24 (20.6) 0.68 (0.45, 1.02) 0.76 (0.50, 1.15) 
 Statin user - high intensity D 491 2.0 8.5 89.2 1,261 74 (58.7) 1.05 (0.82, 1.35) 1.11 (0.86, 1.43)  32 (25.4) 0.92 (0.63, 1.34) 1.03 (0.71, 1.50) 
                    
 Hydro/lipophilic C                   
 Non-user 2,759 - - - 12,369 692 (55.9) Ref - Ref -  398 (32.1) Ref - Ref - 
 Hydrophilic statin user 221 1.8 5.0 88.9 610 41 (67.2) 1.18 (0.68, 1.63) 1.43 (1.04, 1.97)  21 (34.4) 1.16 (0.74, 1.81) 1.35 (0.86, 2.11) 
 Lipophilic statin user 509 2.2 5.8 88.2 1,579 74 (46.9) 0.83 (0.65, 1.06) 0.83 (0.65, 1.06)  31 (19.6) 0.67 (0.46, 0.97) 0.72 (0.49, 1.04) 
 Both 107 2.3 7.9 71.6 236 13 (55.0) 0.98 (0.56, 1.70) 1.21 (0.69, 2.11)  4 (16.9) 0.62 (0.23, 1.66) 0.77 (0.28, 2.08) 
                    
 Hydro/lipophilic - dosing intensity C, E                   
 Non-user 2,759 - - - 12,369 692 (55.9) Ref - Ref -  398 (32.1) Ref - Ref - 
 Hydrophilic statin user                   
  Low intensity 103 1.8 0.7 85.5 290 22 (75.9) 1.33 (0.87, 2.03) 1.60 (1.05, 2.46)  13 (44.8) 1.44 (0.83, 2.51) 1.68 (0.96, 2.94) 
  High intensity D 118 1.8 8.5 91.9 320 19 (59.3) 1.03 (0.65, 1.61) 1.23 (0.78, 1.92)  8 (25.0) 0.92 (0.47, 1.80) 1.07 (0.55, 2.10) 
 Lipophilic statin user                   
  Low intensity 217 2.4 0.5 85.2 805 28 (34.8) 0.62 (0.42, 0.90) 0.63 (0.43, 0.92)  9 (11.2) 0.37 (0.19, 0.72) 0.39 (0.20, 0.76) 
  High intensity D 292 2.1 8.9 90.4 774 46 (59.4) 1.07 (0.80, 1.44) 1.06 (0.79, 1.44)  22 (28.4) 0.95 (0.61, 1.48) 1.05 (0.67, 1.63) 
                    
 Both 107 2.3 7.9 71.6 236 13 (55.0) 0.96 (0.48, 1.93) 1.23 (0.61, 2.48)  4 (16.9) 0.72 (0.23, 2.26) 0.91 (0.29, 2.86) 
                    
Ref: Referent Group, HR: Hazard Ratio, CI: Confidence Interval. 
A) Deaths / 1,000 person years. 
B) Adjusted for age at diagnosis (years); smoking status (never, past, current, unspecified); comorbidity score, tumour stage (I, IIa, IIb, IIIa, IIIb-c); tumour grade (low, intermediate, high, unspecified); ER, PR & HER2 receptor status 
(positive, negative, unspecified); chemotherapy in year post diagnosis (yes, no); anti-oestrogen therapy in year post diagnosis (yes, no); aspirin, bisphosphonate, NSAID & anti-diabetic medication use (yes, no). 
C) Statin exposure lagged by 2 years in analysis. 
D) Statin dosing intensity of ≥ 80% for ≥ 12 consecutive months defined as high dosing intensity. All other statin exposures defined as low dosing intensity  
E) Analysis conducted post-hoc.  
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TABLE 3: SENSITIVITY ANALYSES - UNIVARIATE AND MULTIVARIATE HAZARD RATIOS FOR ASSOCIATION BETWEEN DE-NOVO POST-DIAGNOSTIC STATIN USE AND MORTALITY 
De-novo post-diagnostic 
statin  exposure definitions 
 All-cause mortality  Breast cancer-specific mortality 
N 
Years to  
treatment 
initiation 
(median) 
Years on 
treatment 
(median) 
On-treatment 
exposure 
intensity 
(mean %) 
Follow-up 
(person  
years) 
Deaths  
(rate) A 
Univariate HR  
(95%CI) 
Multivariate HR  
(95%CI) B 
 
Deaths  
(rate) A 
Univariate HR  
(95%CI) 
Multivariate HR  
(95%CI) B 
                    
Sensitivity analysis: yes/no exposure lagged 
by 0, 1, 3 & 4 years 
           
 
      
 Statin exposure – yes/no (lag 0 years)                   
 Non-user 3,038 - - - 18,339 909 (49.6) Ref - Ref -  562 (30.7) Ref - Ref - 
 Statin user 1,205 2.5 5.7 85.6 4,496 230 (51.5) 0.94 (0.81, 1.09) 1.01 (0.87, 1.18)  107 (23.9) 0.78 (0.63, 0.97) 0.86 (0.69, 1.07) 
 Statin exposure – yes/no (lag 1 year)                   
 Non-user 3,058 - - - 15,291 804 (52.6) Ref - Ref -  482 (31.5) Ref - Ref - 
 Statin user 1,033 2.3 6.7 86.0 3,354 183 (54.6) 0.99 (0.84, 1.17) 1.06 (0.89, 1.25)  85 (25.3) 0.85 (0.67, 1.08) 0.94 (0.74, 1.19) 
 Statin exposure – yes/no (lag 3 years)                   
 Non-user 2,425 - - - 9,776 564 (57.7) Ref - Ref -  308 (31.5) Ref - Ref - 
 Statin user 640 1.9 6.1 85.9 1,686 93 (55.2) 0.99 (0.79, 1.25) 1.06 (0.84, 1.33)  40 (23.7) 0.87 (0.62, 1.22) 0.96 (0.68, 1.34) 
 Statin exposure – yes/no (lag 4 years)                   
 Non-user 2,046 - - - 7,540 427 (56.6) Ref - Ref -  221 (29.3) Ref - Ref - 
 Statin user 492 1.7 6.1 85.7 1,117 59 (52.8) 0.96 (0.73, 1.27) 0.99 (0.74, 1.31)  25 (22.4) 0.88 (0.57, 1.35) 0.95 (0.62, 1.46) 
                    
Sensitivity analysis: high intensity exposure  ≥ 
80% for ≥ 24 consecutive months  C 
           
 
      
 Non-user 2,759 - - - 12,369 692 (55.9) Ref - Ref -  398 (32.2) Ref - Ref - 
 Statin user – low intensity 480 2.5 1.6 82.8 1,613 83 (51.5) 0.91 (0.72, 1.14) 0.96 (0.76, 1.21)  37 (22.9) 0.76 (0.54, 1.06) 0.84 (0.60, 1.18) 
 Statin user – high intensity  357 1.8 8.5 91.0 813 45 (55.3) 1.00 (0.73, 1.36) 1.07 (0.78, 1.47)  19 (23.4) 0.88 (0.55, 1.42) 1.02 (0.63, 1.65) 
                    
Sensitivity analysis: no statin exposure in 3 
years prior to diagnosis 
           
 
      
 Statin exposure – yes/no C                   
 Non-user 2,670 - - - 12,096 677 (56.0) Ref - Ref -  392 (32.4) Ref - Ref - 
 Statin user 796 2.2 6.7 86.1 2,307 124 (53.8) 0.96 (0.78, 1.17) 1.03 (0.84, 1.25)  55 (23.8) 0.82 (0.61, 1.10) 0.90 (0.67, 1.21) 
                    
 
Ref: Referent Group, HR: Hazard Ratio, CI: Confidence Interval. 
A) Deaths / 1,000 person years. 
B) Adjusted for age at diagnosis (years); smoking status (never, past, current, unspecified); comorbidity score, tumour stage (I, IIa, IIb, IIIa, IIIb-c); tumour grade (low, intermediate, high, unspecified); ER, PR & HER2 receptor status 
(positive, negative, unspecified); chemotherapy in year post diagnosis (yes, no); anti-oestrogen therapy in year post diagnosis (yes, no); aspirin, bisphosphonate, NSAID & anti-diabetic medication use (yes, no).  
C) Statin exposure lagged by 2 years in analysis. 
 
